
PRODUCT INFORMATION

Cirtuvivint

Item No. 46303

CAS Registry No.:	2143917-62-6
Formal Name:	2-(4-methyl-1-piperazinyl)-N-[6-(1-methyl1H-pyrazol-4-yl)-3-isoquinolinyl]-4-pyridinecarboxamide
Synonym:	SM08502
MF:	$C_{24}H_{25}N_7O$
FW:	427.5
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cirtuvivint is supplied as a solid. A stock solution may be made by dissolving the cirtuvivint in the solvent of choice, which should be purged with an inert gas. Cirtuvivint is slightly soluble (0.1-1 mg/ml) in DMSO.

Description

Cirtuvivint is a dual inhibitor of CDC-like kinases (Clks; IC_{50}s = 7.1, 3.6, 30.9, and 4.3 nM for CLK1, -2, -3, and -4, respectively) and dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs; IC_{50}s = 4.7, 22.4, 40.7, and 86.4 nM for DYRK1A, -1B, -2, and -4, respectively).[1] It is selective for these kinases over DYRK3, cyclin-dependent kinase 5 (Cdk5), casein kinase 1ε (CK1ε), and glycogen synthase kinase 3β (GSK3β; IC_{50}s = 2.1, 3.96, 3.02, and >10 µM, respectively). Cirtuvivint reduces the viability of 26 patient-derived tumor cell lines grown as multi-cell type spheroids (IC_{90}s = 0.2-10 µM).[2] It reduces tumor growth in a KG-1a acute myeloid leukemia (AML) mouse xenograft model and reduces tumor volume in an MV4-11 AML mouse xenograft model at 25 mg/kg.[3]

References

1. Lindberg, M.F., Deau, E., Arfwedson, J., *et al.* Comparative efficacy and selectivity of pharmacological inhibitors of DYRK and CLK protein kinases. *J. Med. Chem.* **66(6)**, 4106-4130 (2023).
2. Teicher, B.A., Dexheimer, T.S., Silvers, T., *et al.* RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids. *Cancer Chemother. Pharmacol.* **95(1)**, 85 (2025).
3. Govindharajulu, J.P., Fluss, S., Hollingshead, M.G., *et al.* Dynamic switching of apoptosis-modulating bim heterodimers in response to BH3 Mimetics in xenograft models of hematologic malignancies. *Mol. Cancer Ther*. **25(9)**, 1537-154 (2026).

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/09/2026

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM